动物造模,青光眼,细胞移植 z-bio 2021-07-14 824

　　A study by the University of Iowa in the United States showed that cell replacement therapy, which can reduce intraocular pressure in glaucoma mice and prevent the loss of nerve cells, may maintain patients’ vision. Glaucoma is the most common cause of irreversible vision loss and blindness in the world. Blindness is caused by the death of retinal ganglion cells due to increased intraocular pressure, which is regulated by trabecular meshwork (TM) cells. Markus Kuehn et al. found that transplantation of stem cell-derived trabecular meshwork (TM) cells can reduce the intraocular pressure of glaucoma mice and prevent the death of retinal ganglion cells. The authors genetically reprogram mouse skin cells, transforming them into induced pluripotent stem cells (iPSC), and then into trabecular meshwork (TM) cells. Then, the author injected the same amount of saline as iPSC-TM cells or control into the eyes of the mice. These mice carry genetic mutations that can cause human glaucoma. Unlike traditional saline injections, this cell replacement therapy prevents the increase in intraocular pressure and maintains the number of trabecular meshwork (TM) cells and retinal ganglion cells for at least 9 weeks. Other evidence suggests that direct contact with transplanted iPSC-TM cells may stimulate the proliferation of trabecular meshwork (TM) cells already present in the eye. The author believes that cell replacement therapy can maintain the vision of glaucoma patients and improve the quality of life by preventing increased intraocular pressure and neuron loss.